Early proactive therapeutic drug monitoring program for management of infliximab in inflammatory bowel disease: long-term durability of treatments

被引：0
|
作者：
Sanchez-Hernandez, J. G. [1 ]
Rebollo, N. [1 ]
Munoz, F. [2 ]
Saez-Fernandez, E. M. [1 ]
Rodriguez-Rodriguez, G. [1 ]
Tapia-Artiles, C. [1 ]
Fernandez-Caballero, R. [1 ]
Calvo, M. V. [1 ]
机构：
[1] Hosp Univ Salamanca, Pharm Serv, Salamanca, Spain
[2] Hosp Clin Univ Salamanca, Gastroenterol Serv, Salamanca, Spain
来源：
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY | 2020年 / 42卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
TDMP002
引用
收藏
页码：232 / 233
页数：2
相关论文
共 50 条
  • [41] Proactive Therapeutic drug monitoring of Infliximab, but not HLA-DQA1*05, predicts clinical outcome in inflammatory bowel disease
    Alonso, I.
    Carrillo Palau, M.
    Vera, B.
    Vela, M.
    Morant, A.
    Ramos, L.
    Reygosa, C.
    Medina Chico, J. S.
    Barrios, Y.
    Franco, A.
    Gutierrez-Nicolas, F.
    Jimenez, A.
    Hernandez-Guerra, M.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I597 - I597
  • [42] Reactive Versus Proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease Patients Treated With Infliximab: A Self-Fulfilling Prophecy
    Headlam, John
    Ford, Alexander C.
    Gracie, David J.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2017, 15 (10) : 1638 - 1638
  • [43] Therapeutic drug monitoring in Paediatric inflammatory bowel disease on maintenance infliximab and adalimumab treatment improves clinical remission with a proactive approach
    Chadokufa, S.
    Sider, S.
    Huggett, B.
    Sawney, T.
    Shah, N.
    Baycheva, M.
    Perez, A. Zambrano
    Acton, N.
    Kiparissi, F.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S381 - S382
  • [44] Inflammatory bowel disease: Short- and long-term treatments
    Bickston, SJ
    Cominelli, F
    DM DISEASE-A-MONTH, 1998, 44 (04): : 144 - 172
  • [45] Is Proactive Therapeutic Drug Monitoring Ready for the Spotlight in Inflammatory Bowel Disease? Follow the Data
    Battat, Robert
    Long, Millie D.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 (10): : 2029 - 2031
  • [46] Proactive therapeutic drug monitoring and pharmacogenetic analysis in inflammatory bowel disease: A systematic review
    Ballesta-Lopez, Octavio
    Centelles-Oria, Maria
    Remedios Marques-Minana, Maria
    Eduardo Megias-Vericat, Juan
    Luis Poveda-Andres, Jose
    FARMACIA HOSPITALARIA, 2021, 45 : 56 - 63
  • [47] Proactive therapeutic drug monitoring and vedolizumab dose optimization in children with inflammatory bowel disease
    Rowland, Patrick
    Mcnicol, Megan
    Kiel, Ashley
    Maltz, Ross M.
    Donegan, Amy
    Dotson, Jennifer L.
    Michel, Hilary K.
    Boyle, Brendan
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2024, 78 (04): : 853 - 861
  • [48] Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease: A Prospective Study
    Paul, Stephane
    Del Tedesco, Emilie
    Marotte, Hubert
    Rinaudo-Gaujous, Melanie
    Moreau, Amelie
    Phelip, Jean-Marc
    Genin, Christian
    Peyrin-Biroulet, Laurent
    Roblin, Xavier
    INFLAMMATORY BOWEL DISEASES, 2013, 19 (12) : 2568 - 2576
  • [49] Therapeutic drug monitoring in 45 children with inflammatory bowel disease on maintenance infliximab treatment
    Rolandsdotter, H.
    Marits, P.
    Sundin, U.
    Wikstrom, A. -C.
    Fagerberg, U.
    Finkel, Y.
    Eberhardson, M.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S363 - S364
  • [50] THE IMPACT OF THERAPEUTIC DRUG MONITORING DURING BIOSIMILAR INFLIXIMAB SWITCH IN INFLAMMATORY BOWEL DISEASE
    Ranjan, Ravi
    Myers, Sally
    Crissop, Linda
    Ritchie, Susan
    Maw, Frances
    Sebastian, Shaji
    Dhar, Anjan
    GUT, 2018, 67 : A74 - A74
12345